Stock Track | Myriad Genetics Tumbles 7.69% After-Hours on Disappointing Q4 Earnings and Executive Transition

Stock Track

02-25

Myriad Genetics (MYGN) stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.

Firstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last year.

Furthermore, Myriad Genetics announced that its President and CEO, Paul J. Diaz, will step down on April 30, 2025, to join private equity firm Cressey & Company as a Managing Partner. The company has appointed its current Chief Operating Officer, Sam Raha, as the new President and CEO, effective April 30. Raha has been with Myriad since December 2023 and was previously the President of Agilent's Diagnostics and Genomics Group. Mark S. Verratti, the current Chief Commercial Officer, will be promoted to Chief Operating Officer.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1109581245"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109581245\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1109581245?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109581245","market":"us","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Tumbles 7.69% After-Hours on Disappointing Q4 Earnings and Executive Transition","media":"Stock Track","content":"<p>Myriad Genetics (MYGN) stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.</p>\n\n<p>Firstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last year.</p>\n\n<p>Furthermore, Myriad Genetics announced that its President and CEO, Paul J. Diaz, will step down on April 30, 2025, to join private equity firm Cressey & Company as a Managing Partner. The company has appointed its current Chief Operating Officer, Sam Raha, as the new President and CEO, effective April 30. Raha has been with Myriad since December 2023 and was previously the President of Agilent's Diagnostics and Genomics Group. Mark S. Verratti, the current Chief Commercial Officer, will be promoted to Chief Operating Officer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Tumbles 7.69% After-Hours on Disappointing Q4 Earnings and Executive Transition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Tumbles 7.69% After-Hours on Disappointing Q4 Earnings and Executive Transition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Myriad Genetics (MYGN) stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.</p>\n\n<p>Firstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last year.</p>\n\n<p>Furthermore, Myriad Genetics announced that its President and CEO, Paul J. Diaz, will step down on April 30, 2025, to join private equity firm Cressey & Company as a Managing Partner. The company has appointed its current Chief Operating Officer, Sam Raha, as the new President and CEO, effective April 30. Raha has been with Myriad since December 2023 and was previously the President of Agilent's Diagnostics and Genomics Group. Mark S. Verratti, the current Chief Commercial Officer, will be promoted to Chief Operating Officer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"","article_id":"1109581245","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109581245","pubTimestamp":1740433012,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Myriad Genetics  stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.Firstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"由于第四季度盈利和高管交接令人失望，Myriad Genetics盘后下跌7.69%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (MYGN) stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.\nFirstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last year.\nFurthermore, Myriad Genetics announced that its President and CEO, Paul J. Diaz, will step down on April 30, 2025, to join private equity firm Cressey & Company as a Managing Partner. The company has appointed its current Chief Operating Officer, Sam Raha, as the new President and CEO, effective April 30. Raha has been with Myriad since December 2023 and was previously the President of Agilent's Diagnostics and Genomics Group. Mark S. Verratti, the current Chief Commercial Officer, will be promoted to Chief Operating Officer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}